HRMY Q3 2023 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$160M+36.7% YoY

Gross Profit

$128M79.8% margin

Operating Income

$65M40.3% margin

Net Income

$38M24.0% margin

EPS (Diluted)

$0.63

QoQ Revenue Growth

+19.4%

Cash Flow

Operating Cash Flow

$63M

Free Cash Flow

$63M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$778M

Total Liabilities

$296M

Stockholders' Equity

$481M

Cash & Equivalents

$325M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$160M	$117M	+36.7%
Gross Profit	$128M	$94M	+35.8%
Operating Income	$65M	$12M	+442.0%
Net Income	$38M	$88M	-56.3%

Geographic Segments

United States

$500M100%